Inovio Pharmaceuticals (INO) Stock Statistics & Valuation Metrics

Inovio Pharmaceuticals has a market cap or net worth of $114.69M. The enterprise value is -$34.82B.

Inovio Pharmaceuticals has 69,091,960 shares outstanding. The number of shares has decreased by -2.65% in one year.

Inovio Pharmaceuticals’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.26%.

The current PE Ratio of Inovio Pharmaceuticals is ―. Inovio Pharmaceuticals’s PEG ratio is 0.00018.

In the last 12 months, Inovio Pharmaceuticals had revenue of 65.34K and earned -84.95B in profits. Earnings per share was -1.81.

In the last 12 months, operating cash flow was -19.44B and capital expenditures -217.63K, giving a free cash flow of -19.44B billion.

Inovio Pharmaceuticals pays an annual dividend of $0.069, resulting in a dividend yield of ―

Inovio Pharmaceuticals upcoming earnings date is May 12, 2026, TBA (Confirmed).

Inovio Pharmaceuticals as a current ratio of 1.40, with Debt / Equity ratio of 38.88%

In the past 12 months, Inovio Pharmaceuticals has paid 0.00 in taxes.

Inovio Pharmaceuticals EV to EBITDA ratio is 406.64, with an EV/FCF ratio of 0.38.

Inovio Pharmaceuticals has $58.51B in cash and marketable securities with $9.37B in debt, giving a net cash position of $49.14B billion.

Gross margin is 0.00%, with operating margin of -132871.32%, and net profit margin of -130000001.53%.

The average price target for Inovio Pharmaceuticals is $4.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy